CTI withdraws Euro application for pacritinib in myelofibrosis

https://thefly.com/landingPageNews.php?id=2857534

Baxter price target raised to $80 from $72 at Piper Jaffray

Piper Jaffray analyst Matt O’Brien raised his price target for Baxter International to $80 after the company’s Q4 results topped expectations on both the top- and bottom-lines. The primary drivers of the revenue beat in the quarter were the company’s Renal Care, Pharma, Advanced Surgery and Acute Therapies, O’Brien tells investors in a research note. Further, he believes Baxter’s domestic Medication Delivery and Nutrition businesses stabilized during the quarter “with progress made towards restoring demand to pre-hurricane levels.” The analyst remains constructive on the stock and reiterates an Overweight rating.
https://thefly.com/landingPageNews.php?id=2857405

Cigna sees FY19 adjusted EPS $16.00-$16.50, consensus $16.75

Sees FY19 adjusted revenue $131.5B-$, consensus $133.37B.
https://thefly.com/landingPageNews.php?id=2857425

Zimmer Biomet sees FY19 adj. EPS $7.70-$7.90, consensus $7.92B

https://thefly.com/landingPageNews.php?id=2857430

Cooper Cos. upgraded to Overweight from Equal Weight at Stephens

Stephens analyst Chris Cooley upgraded Cooper Companies to Overweight and raised his price target to $305 from $270. The analyst believes that the company is positioned to boost its earnings guidance, citing a stronger growth of its single-use daily SiH contact lens sales, above-forecast Paragard sales, and more modest FX-related headwinds than previously anticipated. Fooley adds that the current investor sentiment is “mixed at best”, which could lead to valuation lift in the near term.
https://thefly.com/landingPageNews.php?id=2857471

Tilly’s declares one-time, special cash dividend of $1.00 per share

Tilly’s announced that its Board of Directors has declared a special cash dividend of $1.00 per share, or approximately $29.5M in the aggregate, on the company’s outstanding Class A and Class B common stock. This one-time, special dividend is payable on February 27 to stockholders of record at the close of business on February 15.
https://thefly.com/landingPageNews.php?id=2857481

Merck sees FY19 adjusted EPS $4.57-$4.72, consensus $4.69

https://thefly.com/landingPageNews.php?id=2857503